Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

American Journal of Psychiatry

Volumn 161, Issue 9, 2004, Pages 1642-1649

  Allgulander, Christer ^a   Dahl, Alv A ^b   Austin, Carol ^b   Morris, Philip L P ^b   Sogaard, Jesper A ^b   Fayyad, Rana ^b   Kutcher, Stan P ^b   Clary, Cathryn M ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NAUSEA; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SWEATING; TREATMENT OUTCOME;

EID: 4444345940     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.9.1642     Document Type: Article

References (35)

1. Perugi G, Frare F, Toni C, Ruffolo G, Torti C: Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology 2002; 46:145-149
2. Silverstone PH, Ravindran A (Venlafaxine XR 360 Study Group): Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999; 60:22-28
3. Silverstone PH, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62:523-529
4. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine-XR extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283:3082-3088
5. AlIgulander C, Hackett D, Salinas E: Venlafaxine-XR extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179:15-22
6. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Lyengar MK: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62:350-357
7. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
8. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H: Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45:444-450
9. Cohn JB, Bowden CL, Fisher JG, Rodos JJ: Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986; 80:10-16
10. Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50:884-895
11. Rickels K, Rynn M: Overview and clinical presentation of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24:1-17
12. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD, Steiner H: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280:1752-1756
13. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowtiz MR, Lydiard B: A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10:57-65
14. Pohl RB, Wolkow RM, Clary CM: Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998; 155:1189-1195
15. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55:1010-1016
16. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844
17. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee Y-J, Nandy S, Pecknold JC, Hadrava V, Swinson RP: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:275-281
18. Liebowitz M, DeMartinis N, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:785-792
19. Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158:2008-2014
20. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-326
21. Endicott J, Nee J: Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 1997; 33:13-16
22. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67:361-370
23. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
24. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997; 12:232-241
25. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
26. Ballenger JC: Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60(suppl 22):29-34
27. Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157:968-974
28. Meoni P, Salinas E, Brault Y, Hackett D: Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry 2001; 62: 888-993
29. Barlow DH, Raffa SD, Cohen EM: Psychosocial treatments for panic disorders, phobias, and generalized anxiety disorder, in A Guide to Treatments That Work, 2nd ed. Edited by Nathan PE, Gorman JM. New York, Oxford University Press, 2002, pp 301-336
30. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749-756
31. Yonkers KA, Dyck IR, Warshaw M, Keller MB: Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 2000; 176:544-549
32. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D: Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002; 36:209-217
33. Rapaport MH, Endicott J, Fayyad R, Clary C: Quality of life in anxiety and depressive disorders. Eur Neuropsychopharmacol 2002; 12(suppl 3):S355
34. Kessler RC, DuPont RL, Berglund P, Wittchen H-U: Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156:1915-1923
35. Lepola U, Arató M, Zhu Y, Austin C: Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 2003; 64:654-662